I have received a lot of interest from others on here in my involvement with the Xeljanz trials at Yale.

I thought it would be nice for everyone if I documented my progress on here. 

Xeljanz is a Jak3 inhibitor and is believed to work with alopecia by turning off the distress signal relayed by the hair follicle to the attacking immune system which is the cause of the hairs falling out. Xeljanz comes in a strength of 5mg per pill and a full box contains 60 tablets. The recommended dosage for arthritis is 1 tablet in the morning and another in the evening each day.

The trial is set in a series of stages and there are requirements before participating. These include monthly visits and blood tests every 2 weeks. Dr Brett King is absolutely fantastic and is an inspiration to me. His positivity and enthusiasm gives me the much needed hope I have craved for over a decade. I have been put on a low dose to start with which is 1 tablet every other day. My dosage has now been increased to 1 tablet every day and next month it could be increased to 2 tablets per day depending on the results. 

I have completed my first month and have already noticed my alopecia has stabilised . I have not lost any existing hairs. In addition to this I have seen little hairs growing in my chest area as well as eyebrows. Fingers crossed! To date, I have experienced no side effects.


Views: 899441

Reply to This

Replies to This Discussion

Thanks Kevin what is pf?

this is the pfizer jak for alopecia pf-06651600 a jak 3 and the ctp 543 is a jak 2 a derivative of ruxolotinib I think it is more effective



Lilly’s baricitinib (olumiant) is in phase 3 and is likely to be approved first. In the next year or so. Pfizer’s ritlecitinib is also in phase 3 and close to being approved. CTP-543 just began phase 3 so it probably won’t be approved until after the other 2. This is according to my dermatologist and Dr. Brett King who discovered that jak inhibitors help alopecia patients. 

baracitinib will not be approved due to side effects like xeljanz,
the pf of pfizer starts phase 3 all like ctp 543 who has already started phase 3, it will be the 2 who will be approved for alopecia at the end of phase 3 he will apply for marketing in 2023 , so probably in 2024 at best

That is really long time

Why 2023 if they are already Phase 3

Kevin what credentials do you have to make the statement that "Baracitinib will not be approved" so firmly? Is it your opinion or are you a professional in the field? 

Kevin has been one of the longest standing contributors on this forum, also o e of the only people posting to have used baricitinib - he was also the one who actively undertook testing on beacon generic tofacitinib, and has been involved  in trials prior to this forum becoming popular. I think a lot of his info comes from doctors and specialists he’s met along the way, but in the world of Alopecia treatments often that is the only way to find out information as trials are few and far between and are limited by a whole bunch of criteria. 

I don’t think tofacitinib will lose FDA approval for the most part (treating RA, chronic psoriasis). It is hard to see it being approved for Alopecia though, given the lack of interest in treating by so many dermatologists.

That said other jak varieties are in the pipeline - so all hope is not lost AND you will still be able to get generics from Beacon, who will continue to produce regardless of the FDA. 

The study was worded in such a way that is frightening- but remember this is in population group who are usually RA which often has very devastating effects on heart health, blood pressure, wasting etc, the risks are different from general population. In addition it was a test against another immune suppressant (a biological I believe), and the risk was only marginally higher in the tofacitinib group vs biological group.  A statement of significant risk on a medical trial is not the same as a significant risk in the general population, it is scientific terms used to describe minor difference amongst medications.


thank you frida he published a new article concerning xeljanz's warning no worry he will not be withdrawn from the market at worst a contraindication will be put on the box.

by then we will have our own medicine for alopecia

I am in the same situation as you I would also like the drugs to be approved as soon as possible, but you have to be realistic and not give false hope,
as far as xeljanz is concerned it will never be approved for alopecia, that's for sure
baracitinib my dermatologist told me he is trying but it is not a certainty because of the side effect it also a warning about venous thrombosis.

Now the jaks specially designed for alopecia
ctp 543 is in phase 3 a friend of mine is waiting for a call from his dermatologist in paris to start the clinical trial in february normally this was delayed because of covid 19 in 2023 a marketing request will be made ask by pharmaceuticals concert after I do not know the duration.
to give you an idea phase 2 started in 2017 and it's finished in 2020.
a vaccine or drug take 8 to 10 years before it is marketed.

concerning pfizer the pf06651600
it also begins phase 3.

those are the 2 jaks specially designed for alopecia is that they will be approved with certainty within 2 to 4 years.

for those who do not wish to wait I invite them to do as the vast majority of users here to buy the generic of xeljanz or baracitinib as I do or to participate in the clinical trials but I think that the trials are closed in in any case in France it is to close for the ctp 543.



Any mention of products and services on Alopecia World is for informational purposes only; it does not imply a recommendation or endorsement by Alopecia World. Nor should any statement or representation on this site be construed as professional, medical or expert advice, or as pre-screened or endorsed by Alopecia World. Alopecia World is not responsible or liable for any of the views, opinions or conduct, online or offline, of any user or member of Alopecia World.

© 2021   Created by Alopecia World.   Powered by

Badges  |  Report an Issue  |  Terms of Service